We are international
Donate
TEXT SIZE   
back

ASCO 2012: Dr. Orlowski - Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma
Robert Orlowski, MD
MD Anderson Cancer Center
Houston, Texas, USA
06.26.12


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles